Number of the records: 1
dasatinib
SYS d000069439 LBL 00000cz--a2200181n--4500 005 20250606221746.7 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 065 $a D02.886.675.184 065 $a D03.383.129.708.198 065 $a D03.383.742.148 066 $a 01 $c 03 150 $a dasatinib $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a BMS 354825 $2 slo 450 $w v $a dazatinib $2 slo 550 $7 sllk_us_auth*d000970 $Y Antineoplastic Agents $w P $a antineoplastiká 550 $7 sllk_us_auth*d000092004 $Y Tyrosine Kinase Inhibitors $w P $a inhibítory tyrozínkináz 665 $a 2016 (2004) $2 eng 680 9-
$i A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. $2 eng 750 -2
$a Dasatinib $2 eng 980 $x M
Number of the records: 1